Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Amortization - Intangibles (2017 - 2022)

Avalo Therapeutics filings provide 6 years of Amortization - Intangibles readings, the most recent being $38000.0 for Q1 2022.

  • On a quarterly basis, Amortization - Intangibles fell 91.04% to $38000.0 in Q1 2022 year-over-year; TTM through Dec 2022 was $38000.0, a 97.54% decrease, with the full-year FY2022 number at $38000.0, down 97.54% from a year prior.
  • Amortization - Intangibles hit $38000.0 in Q1 2022 for Avalo Therapeutics, down from $266000.0 in the prior quarter.
  • In the past five years, Amortization - Intangibles ranged from a high of $1.2 million in Q2 2018 to a low of -$1.5 million in Q4 2018.
  • Median Amortization - Intangibles over the past 5 years was $404000.0 (2020), compared with a mean of $381973.3.
  • Biggest five-year swings in Amortization - Intangibles: plummeted 471.82% in 2018 and later surged 122.51% in 2019.
  • Avalo Therapeutics' Amortization - Intangibles stood at -$1.5 million in 2018, then surged by 122.51% to $334753.0 in 2019, then surged by 50.26% to $503000.0 in 2020, then tumbled by 47.12% to $266000.0 in 2021, then crashed by 85.71% to $38000.0 in 2022.
  • The last three reported values for Amortization - Intangibles were $38000.0 (Q1 2022), $266000.0 (Q4 2021), and $428000.0 (Q3 2021) per Business Quant data.